Presentation delivered by Dr Eibhlin Connolly, Deputy Chief Medical Officer at the Department of Health and Children at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the Advanced Training and Conference on Health Economics (24 June 2015, Budapest, Hungary)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the Advanced Training and Conference on Health Economics (24 June 2015, Budapest, Hungary)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
This presentation was made by Marion DEVAUX at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Progress in and priorities for implementing the regional plans for the health sector response to HIV and hepatitis, Dr Masoud Dara, Acting Director, Communicable Diseases Department (69th session of the WHO Regional Committee for Europe)
As part of the IFPRI Egypt Seminar in partnership with the FAO: “Food Policies and their Implications on Overweight and Obesity Trends in Selected Countries in MENA Region”
Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting on Interdepartmental Plan for Public Health of Catalonia (PINSAP) Strategy and Programme, held in Barcelona, Spain on 14 February 2014.
Performance measurement and KPI setting - Valikhan Akhmetov, KazakhstanOECD Governance
This presentation was made by Valikhan Akhmetov, KazakhstanN, at the 3rd Health Systems Joint Network meeting for Central, Eastern and South-eastern European Countries held in Vilnius, Lithuania, on 25-26 April 2019
This presentation was made by Marion DEVAUX at the 5th Meeting of the joint OECD DELSA/GOV Network on Fiscal Sustainability of Health Systems held on 4-5 February 2016 at the OECD Conference Centre in Paris.
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Progress in and priorities for implementing the regional plans for the health sector response to HIV and hepatitis, Dr Masoud Dara, Acting Director, Communicable Diseases Department (69th session of the WHO Regional Committee for Europe)
As part of the IFPRI Egypt Seminar in partnership with the FAO: “Food Policies and their Implications on Overweight and Obesity Trends in Selected Countries in MENA Region”
Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting on Interdepartmental Plan for Public Health of Catalonia (PINSAP) Strategy and Programme, held in Barcelona, Spain on 14 February 2014.
Performance measurement and KPI setting - Valikhan Akhmetov, KazakhstanOECD Governance
This presentation was made by Valikhan Akhmetov, KazakhstanN, at the 3rd Health Systems Joint Network meeting for Central, Eastern and South-eastern European Countries held in Vilnius, Lithuania, on 25-26 April 2019
Preventing Illness 2015 Commissioning a Sustainable Health System4 All of Us
Preventing Illness 2015 was held at The Wellcome Trust on Tuesday November 24th the conference looked at how we can create a preventative health system which focuses on reducing illness, improves sustainability, improves public health whilst joining health and social care together and reducing pressure on our NHS.
Presentation delivered by Dr Zsuzsanna Jakab, Regional Director WHO Europe, at the international health forum (Ashgabat, Turkmenistan, 21-22 July 2015)
This presentation is part of the report presented by the WHO Regional Director Zsuzsanna Jakab at the 63rd session of the WHO Regional Committee for Europe in Çeşme Izmir, Turkey, on 16 September 2013.
Yvonne Doyle - High Impact Health Interventions Age UK
Yvonne Doyle, Director of Public Health, Public Health England - presentation from Age UK's For Later Life conference, 25th April 2013.
For more information, view: www.ageuk.org.uk/forlaterlife
This presentation by Ankit KUMAR was made at the 3rd Joint DELSA/GOV Health Meeting, Paris 24-25 April 2014. Find out more at www.oecd.org/gov/budgeting/3rdmeetingdelsagovnetworkfiscalsustainabilityofhealthsystems2014.htm
mHealth israel_EU Go-To-Market for Digital Health, Julien Venne, European Con...Levi Shapiro
Presentation for mHealth Israel about "EU Go-To-Market for Digital Health", by Julien Venne, Strategic Advisory, European Connected Healthcare Alliance, Oct, 2016
Similar to The health challenges facing Irish society (20)
Delivered by Mr David Gallagher, IPHA President, at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Delivered by Prof Frances Ruane, Chairperson of the Expert Group on Resource Allocation in the Health Sector, Executive Director of the ESRI at the IPHA Annual Meeting 2010.
Delivered by Dr Michael Barry, National Centre for Pharmacoeconomics at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Delivered by Dr Colin Doherty, Epilepsy Clinical Lead, Health Service Executive at the IPHA Annual Meeting 2010 during the Session entitled "Ensuring the best health outcomes for Irish patients while securing value for money".
Pharmaceutical Healthcare Facts and Figures 2010 provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health.
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.
Presentation delivered by Mr Shaun Flanagan, Corporate Pharmaceutical Unit, Health Service Executive at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
IPHA Healthcare Facts and Figures provides detailed facts and figures about healthcare in Ireland and the pharmaceutical and healthcare industry both nationally and globally across the following areas: Healthcare Today, Self-Care Today, Demographic Trends, Healthcare Tomorrow, The Medicines Industry, Medicines in the Community and Medicines and Global Health
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
The health challenges facing Irish society
1. Health Challenges for Irish Society Dr Eibhlín Connolly Deputy Chief Medical Officer Department of Health and Children IPHA Conference 12-11-09
2.
3.
4. TOTAL PUBLIC HEALTH EXPENDITURE, 1999 TO 2008 Sources: "Estimated Non-Capital Expenditure 1999-2004" www.dohc.ie. From 2005, Revised Estimates for Public Services and HSE Reports on Capital Programme
5. NUMBER OF PRESCRIPTION ITEMS DISPENSED UNDER PRIMARY CARE REIMBURSEMENT SERVICE, 1998 TO 2007 Source: General Medical Services (Payments) Board/ National Shared Services Primary Care Reimbursement Service
6. CONSULTANT AND NON-CONSULTANT HOSPITAL DOCTORS EMPLOYED WITHIN THE PUBLIC HEALTH SERVICES, 2000 TO 2009 Source: Personnel Census, Department of Health and Children
7.
8.
9.
10. LIFE EXPECTANCY AT BIRTH FOR IRELAND AND EU, 1980 TO 2006 Expectancy in Years at Birth for Ireland and EU, 1980 to 2006 Source: European Health For All database, WHO Regional Office for Europe, Copenhagen, Denmark.
11. AGE-STANDARDISED DEATH RATES FOR SELECTED CAUSES, 1970 TO 2008 Source: Central Statistics Office and European Health For All database, WHO Regional Office for Europe, Copenhagen, Denmark.
15. ALCOHOL AND CIGARETTE CONSUMPTION PER ANNUM, PER CAPITA OVER 15 YEARS OLD, 1986-2006 Source: Revenue Commissioners Statistical Report 2007, CSO (population data) Note: (i) Alcohol is measured in terms of pure alcohol consumed, based on sales of beer, cider, wine and spirits. (ii) Smoking ban in workplaces was introduced in March 2004